DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Pantoprazole Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Pantoprazole is the third proton pump inhibitor marketed globally. Compared with omeprazole, it has higher selectivity and bioavailability. Pantoprazole is more stable than omeprazole and lansola under weak acid conditions. The product of Pantoprazole, developed by Byk Gulden of Germany, can treat duodenal ulcer; gastric ulcer; moderate and severe reflux esophagitis. It was approved for listing in China in 1999. By the end of 2020, there were several manufacturers in the Chinese Pantoprazole market.

According to the market research, the sales value of pantoprazole in the Chinese market has declined continuously from 2016 to 2020, and its sales value reached CNY 1.162 billion in 2020. The sales value of pantoprazole in the Chinese market has shown an overall upward trend from 2016 to 2020, with a CAGR of 3.06% from 2016 to 2020.

The analyst expects that with the effective alleviation of the COVID-19 epidemic, the sales of pantoprazole will have a restorative growth from 2016 to 2020. Pantoprazole has the advantages of stable curative effect, good acid suppression effect, and small short-term side effects. Therefore, the sales of pantoprazole in China will maintain a growth trend in the future.

Topics Covered:

• The impact of COVID-19 on China's Pantoprazole market
• Sales value of China's Pantoprazole 2016-2020
• Competitive landscape of China's Pantoprazole market
• Prices of Pantoprazole in China
• Prices of Pantoprazole in China by regions and manufacturers
• Analysis of factors affecting the development of China's Pantoprazole market
• Prospect of China's Pantoprazole market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Pantoprazole

1.1 Indications for Pantoprazole

1.2 Development of Pantoprazole in China

1.3 Governmental Approval of Pantoprazole in China

1.4 The Impact of COVID-19 on Pantoprazole sales in China

2 Sales of Pantoprazole in China, 2016-2020

2.1 Sales Value of Pantoprazole

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Pantoprazole

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Pantoprazole by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Enteric-coated Tablets

2.3.3 Enteric-coated Capsules

3 Analysis of Major Pantoprazole Manufacturers in China in 2020

3.1 Analysis of Market Share of Major Pantoprazole Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Hangzhou Sino American Huadong Pharmaceutical Co., Ltd.

3.2.1 Enterprise Profile

3.2.2 Sales of Panlisu (Hangzhou Sino American Huadong Pharmaceutical Co., Ltd.'s Pantoprazole) in China

3.3 Nycomed GmbH

3.3.1 Enterprise Profile

3.3.2 Sales of PANTOLOC (Nycomed GmbH's Pantoprazole) in China

3.4 Yangtze River Pharmaceutical Group Co Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of Weidi (Yangtze River Pharmaceutical Group Co Ltd.'s Pantoprazole) in China

3.5 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd.

3.5.1 Enterprise Profile

3.5.2 Sales of Nuoke (Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd.'s Pantoprazole) in China

3.6 Chengdu Tiantaishan Pharmaceutical Co., Ltd.

3.6.1 Enterprise Profile

3.6.2 Sales of Zhuodi (Chengdu Tiantaishan Pharmaceutical Co., Ltd.'s Pantoprazole) in China

4 Prices of Pantoprazole for Different Manufacturers in China, 2020-2021

4.1 Hangzhou Sino American Huadong Pharmaceutical Co., Ltd. (Panlisu)

4.2 Nycomed GmbH (PANTOLOC)

4.3 Yangtze River Pharmaceutical Group Co Ltd. (Weidi)

4.4 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. (Nuoke)

4.5 Chengdu Tiantaishan Pharmaceutical Co., Ltd. (Zhuodi)

5 Prospect of Chinese Pantoprazole Market, 2021-2025

5.1 Influential Factors of Chinese Pantoprazole Market Development

5.1.1 The Impact of COVID-19 on Chinese Pantoprazole Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/q0fbmn

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900